Suppr超能文献

慢性肾脏病中钙敏感受体病的治疗:一项系统评价和荟萃分析。

Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis.

作者信息

Udomkarnjananun Suwasin, Kongnatthasate Kitravee, Praditpornsilpa Kearkiat, Eiam-Ong Somchai, Jaber Bertrand L, Susantitaphong Paweena

机构信息

Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Department of Medicine, St. Elizabeth's Medical Center, Boston, Massachusetts, USA.

出版信息

Kidney Int Rep. 2018 Oct 9;4(2):231-244. doi: 10.1016/j.ekir.2018.10.002. eCollection 2019 Feb.

Abstract

BACKGROUND

Calciphylaxis is a life-threatening complication of chronic kidney disease (CKD). To inform clinical practice, we performed a systematic review of case reports, case series, and cohort studies to synthesize the available treatment modalities and outcomes of calciphylaxis in patients with CKD.

METHODS

Electronic databases were searched for studies that examined the uses of sodium thiosulfate, surgical parathyroidectomy, calcimimetics, hyperbaric oxygen therapy, and bisphosphonates for calciphylaxis in patients with CKD, including end-stage renal disease. For cohort studies, the results were synthesized quantitatively by performing random-effects model meta-analyses.

RESULTS

A total of 147 articles met the inclusion criteria and were included in the systematic review. There were 90 case reports (90 patients), 20 case series (423 patients), and 37 cohort studies (343 patients). In the pooled cohorts, case series, and case reports, 50.3% of patients received sodium thiosulfate, 28.7% underwent surgical parathyroidectomy, 25.3% received cinacalcet, 15.3% underwent hyperbaric oxygen therapy, and 5.9% received bisphosphonates. For the subset of cohort studies, by meta-analysis, the pooled risk ratio for mortality was not significantly different among patients who received sodium thiosulfate (pooled risk ratio [RR] 0.89; 95% confidence interval [CI] 0.71-1.12), cinacalcet (pooled RR 1.04; 95% CI 0.75-1.42), hyperbaric oxygen therapy (pooled RR 0.89; 95% CI 0.71-1.12), and bisphosphonates (pooled RR 0.77; 95% CI 0.44-1.32), and those who underwent surgical parathyroidectomy (pooled RR 0.88; 95% CI 0.69-1.13).

CONCLUSION

This systematic review found no significant clinical benefit of the 5 most frequently used treatment modalities for calciphylaxis in patients with CKD. Randomized controlled trials are needed to test the efficacy of these therapies.

摘要

背景

钙化防御是慢性肾脏病(CKD)的一种危及生命的并发症。为指导临床实践,我们对病例报告、病例系列和队列研究进行了系统评价,以综合CKD患者钙化防御的现有治疗方式及结局。

方法

检索电子数据库,查找有关硫代硫酸钠、手术甲状旁腺切除术、拟钙剂、高压氧治疗和双膦酸盐在CKD患者(包括终末期肾病患者)中用于钙化防御的研究。对于队列研究,通过进行随机效应模型荟萃分析对结果进行定量综合。

结果

共有147篇文章符合纳入标准并被纳入系统评价。其中有90篇病例报告(90例患者)、20篇病例系列(423例患者)和37篇队列研究(343例患者)。在汇总的队列、病例系列和病例报告中,50.3%的患者接受了硫代硫酸钠治疗,28.7%的患者接受了手术甲状旁腺切除术,25.3%的患者接受了西那卡塞治疗,15.3%的患者接受了高压氧治疗,5.9%的患者接受了双膦酸盐治疗。对于队列研究的子集,通过荟萃分析,接受硫代硫酸钠治疗的患者(汇总风险比[RR]0.89;95%置信区间[CI]0.71 - 1.12)、接受西那卡塞治疗的患者(汇总RR 1.04;95%CI 0.75 - 1.42)、接受高压氧治疗的患者(汇总RR 0.89;95%CI 0.71 - 1.12)、接受双膦酸盐治疗的患者(汇总RR 0.77;95%CI 0.44 - 1.32)以及接受手术甲状旁腺切除术的患者(汇总RR 0.88;95%CI 0.69 - 1.13)之间死亡的汇总风险比无显著差异。

结论

该系统评价发现CKD患者钙化防御最常用的5种治疗方式无显著临床益处。需要进行随机对照试验来检验这些疗法的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ced7/6365410/4fd2bd3af3e5/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验